Allakos

Allakos tumbles after skin disease drug fails mid-stage studies
Reuters
Tue, 01/16/24 - 09:24 am
Allakos
clinical trials
lirentelimab
dermatology
atopic dermatitis
Scratching the surface of the urticaria pipeline
EP Vantage
Thu, 07/20/23 - 10:00 am
chronic urticaria
Sanofi
Dupixent
Regeneron
Novartis
Roche
Xolair
Allakos
AstraZeneca
Celldex Therapeutics
Chronic hives: Four major clinical trials to watch in 2023
Clinical Trials Arena
Wed, 05/3/23 - 11:53 am
chronic hives
chronic urticaria
clinical trials
Sanofi
Regeneron
dupilumab
Amgen
tezepelumab
Allakos
lirentelimab
Celldex Therapeutics
barzolvolimab
After flunking studies last year, Allakos’ failed phase 3 EoDyssey sinks gastrointestinal program
Fierce Biotech
Fri, 09/9/22 - 11:00 am
Allakos
clinical trials
lirentelimab
duodenitis
eosinophilic gastritis
oesophagitis
Doomsday for Allakos
EP Vantage
Wed, 12/22/21 - 11:03 am
Allakos
lirentelimab
3 Biotech Stocks With Huge Catalysts Incoming
Motley Fool
Fri, 10/22/21 - 11:19 am
BeyondSpring
Allakos
Deciphera
plinabulin
lirentelimab
Qinlock
Some of biopharma’s biggest assets face a solo existence
EP Vantage
Thu, 11/19/20 - 08:27 pm
Allakos
lirentelimab
clinical trials
3 Healthcare IPOs From 2018 That Have Already Doubled
Motley Fool
Wed, 09/18/19 - 09:49 am
IPOs
Guardant Health
Allakos
Twist Bioscience
No Enigma in mid-stage success, Allakos insists
EP Vantage
Mon, 08/5/19 - 11:16 am
Allakos
AK002
eosinophilic gastritis
gastroenteritis
A unicorn joins this week’s stampede of biotechs into the red-hot Nasdaq casino
Endpoints
Mon, 07/16/18 - 09:11 am
biotech
IPOs
NASDAQ
Allakos
Constellation Pharma
Crinetics Pharmaceuticals
Replimune
Rubius Therapeutics